Novel Potential Retinoid X Receptor Agonists 2

Peter Jurutka (Inventor), Pamela Marshall (Inventor), Carl Wagner (Inventor)

Research output: Patent


Bexarotene (Targretin) is a synthetic retinoid analog used to treat cutaneous T-cell lymphoma (as well as off label to treat other types of cancer). Moreover, recent research may show great potential in its use for treatment of Alzheimers disease. Bexarotene is especially effective because it has specific high affinity for retinoid X receptors (RXR), enabling regulation of RXR genes to slow or stop cell proliferation of cancer cells. Despite these advantages, there are major drawbacks to the use of Bexarotene due to side effects which include hypothyroidism, hyperlipidemia, and cutaneous toxicity. Researchers at Arizona State University have developed slightly more potent analogs that may provide alternatives to Bexarotene. These analogs have a higher selectivity for the retinoid X receptor versus the retinoic acid receptor (RAR). Additionally, in astrocytes and microglia, these Bexarotene analogs increase expression of ApoE and highly lipidated HDLs, which then promote clearance of amyloid beta in the brain. These new analogs may provide viable and efficacious alternatives to Bexarotene for cancer and Alzheimers disease treatment. Potential Applications Anti-cancer treatment Drug discovery May be useful in treatment of Alzheimers Disease May be useful in treatment of non-insulin dependent diabetes mellitus Benefits and Advantages Several analogs demonstrate higher affinity/activation for RXR than Bexarotene Dowload Original PDF For more information about the inventor(s) and their research, please see Dr. Wagner's departmental webpage
Original languageEnglish (US)
StatePublished - Dec 20 2011


Dive into the research topics of 'Novel Potential Retinoid X Receptor Agonists 2'. Together they form a unique fingerprint.

Cite this